Literature DB >> 27438535

Chronic Treatment with Isoniazid Causes Protoporphyrin IX Accumulation in Mouse Liver.

Madhav Sachar1, Feng Li2, Ke Liu1, Pengcheng Wang1, Jie Lu1, Xiaochao Ma1.   

Abstract

Isoniazid (INH) can cause hepatotoxicity. In addition, INH is contraindicated in patients suffering from porphyrias. Our metabolomic analysis revealed that chronic treatment with INH in mice causes a hepatic accumulation of protoporphyrin IX (PPIX). PPIX is an intermediate in the heme biosynthesis pathway, and it is also known as a hepatotoxin. We further found that INH induces delta-aminolevulinate synthase 1 (ALAS1), the rate-limiting enzyme in heme biosynthesis. We also found that INH downregulates ferrochelatase (FECH), the enzyme that converts PPIX to heme. In summary, this study illustrated that chronic treatment with INH causes PPIX accumulation in mouse liver in part through ALAS1 induction and FECH downregulation. This study also highlights that drugs can disrupt the metabolic pathways of endobiotics and increase the risk of liver damage.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27438535      PMCID: PMC5316289          DOI: 10.1021/acs.chemrestox.6b00121

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  25 in total

1.  Measurement of ALA synthase activity.

Authors:  P R Sinclair; N Gorman; N W Cornell
Journal:  Curr Protoc Toxicol       Date:  2001-05

2.  Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization.

Authors:  J Y Chien; K E Thummel; J T Slattery
Journal:  Drug Metab Dispos       Date:  1997-10       Impact factor: 3.922

3.  Ferrochelatase activity in human lymphocytes, as quantified by a new high-performance liquid-chromatographic method.

Authors:  E Rossi; K A Costin; P Garcia-Webb
Journal:  Clin Chem       Date:  1988-12       Impact factor: 8.327

4.  Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model.

Authors:  Saïd Lyoumi; Marie Abitbol; Dominique Rainteau; Zoubida Karim; Florence Bernex; Vincent Oustric; Sarah Millot; Philippe Lettéron; Nicholas Heming; Laurent Guillmot; Xavier Montagutelli; Gilles Berdeaux; Laurent Gouya; Raoul Poupon; Jean-Charles Deybach; Carole Beaumont; Hervé Puy
Journal:  Gastroenterology       Date:  2011-07-14       Impact factor: 22.682

5.  Oxidative stress, Nrf2 and keratin up-regulation associate with Mallory-Denk body formation in mouse erythropoietic protoporphyria.

Authors:  Amika Singla; David S Moons; Natasha T Snider; Elizabeth R Wagenmaker; V Bernadene Jayasundera; M Bishr Omary
Journal:  Hepatology       Date:  2012-04-25       Impact factor: 17.425

6.  Measurement of ferrochelatase activity.

Authors:  S Taketani
Journal:  Curr Protoc Toxicol       Date:  2001-05

7.  CYP2E1 mediated isoniazid-induced hepatotoxicity in rats.

Authors:  Jiang Yue; Ren-xiu Peng; Jing Yang; Rui Kong; Juan Liu
Journal:  Acta Pharmacol Sin       Date:  2004-05       Impact factor: 6.150

8.  Effect of rifampin, phenobarbital pretreatment, and acetylator phenotype on acetylisoniazid metabolism in the rabbit.

Authors:  B H Thomas; W Zeitz; L W Whitehouse
Journal:  Can J Physiol Pharmacol       Date:  1987-03       Impact factor: 2.273

9.  Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy.

Authors:  L Teng; M Nakada; S-G Zhao; Y Endo; N Furuyama; E Nambu; I V Pyko; Y Hayashi; J-I Hamada
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

10.  Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.

Authors:  Feng Li; Jie Lu; Jie Cheng; Laiyou Wang; Tsutomu Matsubara; Iván L Csanaky; Curtis D Klaassen; Frank J Gonzalez; Xiaochao Ma
Journal:  Nat Med       Date:  2013-03-10       Impact factor: 53.440

View more
  11 in total

1.  The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.

Authors:  Christopher Trent Brewer; Lei Yang; Anne Edwards; Yan Lu; Jonathan Low; Jing Wu; Richard E Lee; Taosheng Chen
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

2.  The Opportunities of Metabolomics in Drug Safety Evaluation.

Authors:  Pengcheng Wang; Amina I Shehu; Xiaochao Ma
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

3.  Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.

Authors:  Charles J Parker; Robert J Desnick; Montgomery D Bissel; Joseph R Bloomer; Ashwani Singal; Laurent Gouya; Herve Puy; Karl E Anderson; Manisha Balwani; John D Phillips
Journal:  Mol Genet Metab       Date:  2019-07-31       Impact factor: 4.797

Review 4.  Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.

Authors:  Ruizhi Gu; Alina Liang; Grace Liao; Isabelle To; Amina Shehu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2022-02-27       Impact factor: 3.579

5.  Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD+ in the Liver.

Authors:  Junjie Zhu; Jie Lu; Hung-Chun Tung; Ke Liu; Jianhua Li; Denis M Grant; Wen Xie; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2020-10-05       Impact factor: 3.922

6.  Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.

Authors:  Pengcheng Wang; Amina I Shehu; Jie Lu; Rujuta H Joshi; Raman Venkataramanan; Kim S Sugamori; Denis M Grant; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2017-09-06       Impact factor: 5.858

7.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15

Review 8.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

9.  NR1I2 genetic polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity: A systematic review and meta-analysis.

Authors:  Miaomiao Yang; Yunliang Qiu; Yanyu Jin; Wenpei Liu; Qingliang Wang; Honggang Yi; Shaowen Tang
Journal:  Pharmacol Res Perspect       Date:  2020-12

10.  High-Performance Near-Infrared Fluorescent Secondary Antibodies for Immunofluorescence.

Authors:  Cynthia L Schreiber; Dong-Hao Li; Bradley D Smith
Journal:  Anal Chem       Date:  2021-02-10       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.